Crossmark Global Holdings Inc. acquires 196 shares of IQVIA Holdings Inc. (NYSE:IQV)

Crossmark Global Holdings Inc. raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 1.6% during the second quarter, HoldingsChannel reports. The institutional investor owned 12,319 shares of the medical research company’s stock after purchasing an additional 196 shares during the quarter. The holdings of Crossmark Global Holdings Inc. holdings in IQVIA were worth $2,604,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Versant Capital Management Inc boosted its stake in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in IQVIA in the second quarter valued at approximately $27,000. Rise Advisors LLC bought a new stake in IQVIA in the 1st quarter valued at about $31,000. Riverview Trust Co bought a new stake in IQVIA in the 1st quarter valued at about $32,000. Finally, Covestor Ltd raised its stake in IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 48 shares in the last quarter. 89.62% of shares are owned by institutional investors.

Indoor activity

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Insiders own 1.60% of the company’s shares.

Analyst upgrades and downgrades

Several equities research analysts have commented on the stock. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and cut their price target for the company from $266.00 to $242.00 in a research note on Wednesday, the 24th July. Argus raised shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Barclays boosted their price objective on shares of IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Goldman Sachs Group assumed coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective for the company. Finally, Robert W. Baird raised their price objective on shares of IQVIA from $235.00 to $251.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 23rd . Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Moderate Buy” and an average target price of $265.67, according to MarketBeat.com.

Read our latest review of IQVIA

IQVIA stock performance

Shares of IQV stock opened at $251.54 on Friday. The stock has a market cap of $45.83 billion, a P/E ratio of 34.36, a P/E/G ratio of 2.26 and a beta of 1.49. The company has a fifty day moving average price of $231.33 and a two hundred day moving average price of $234.20. IQVIA Holdings Inc. it has a one year low of $167.42 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85, and a quick ratio of 0.85.

IQVIA (NYSE:IQV – Get Your Free Report ) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s revenue rose 2.3% year-over-year. In the same period last year, the firm earned $2.22 per share. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.24 EPS for the current year.

IQVIA profile

(Free report)

IQVIA Holdings Inc is committed to providing advanced analytics, technology solutions and clinical research services to the life sciences industry in the Americas, Europe, Africa and Asia-Pacific. It operates through three segments: Technology Solutions and Analytics, Research and Development Solutions, and Medical Solutions and Contract Sales.

Featured stories

Want to see what other hedge funds hold IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for IQVIA Holdings Inc. (NYSE:IQV – Free Report).

Get news and reviews for IQVIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IQVIA and related companies with MarketBeat.com’s FREE daily email newsletter.